7/1/2021 8:12:22 AM
Aileron Therapeutics Begins Phase 1b Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer
4/3/2018 2:28:41 PM
Jefferies Is Increasing Aileron Therapeutics, Inc. (ALRN) FY19 Estimate To -2.26 From -3.01
4/3/2018 2:28:24 PM
Jefferies Is Increasing Aileron Therapeutics, Inc. (ALRN) FY18 Estimate To -2.24 From -2.36
11/9/2017 8:26:47 PM
Jefferies Is Lowering Aileron Therapeutics, Inc. (ALRN) FY19 Estimate To -3.01 From -2.65
11/9/2017 8:26:13 PM
Jefferies Is Lowering Aileron Therapeutics, Inc. (ALRN) FY18 Estimate To -2.36 From -2.05
7/24/2017 7:16:18 AM
Jefferies Starts Aileron Therapeutics, Inc. (ALRN) At Buy With $20 Price Target